Schrodinger (SDGR) Stock Price, News & Analysis

Company Overview

Schrödinger, Inc. is a life sciences and materials discovery company that specializes in the application of physics-based computational platforms to accelerate drug discovery and advanced materials design. Founded in 1990 by Professor Richard A. Friesner, Schrödinger has developed a suite of proprietary software tools—such as Maestro for molecular modeling, Glide for molecular docking and Jaguar for quantum chemistry calculations—that enable scientists to predict molecular behavior with high accuracy. These platforms are deployed on-premises or via cloud-based subscriptions, catering to pharmaceutical, biotechnology and materials science clients worldwide.

Beyond its software offerings, Schrödinger collaborates with industry partners through research alliances, joint ventures and sponsored research agreements. Its integrated business model couples software licensing with contract research services, allowing clients to leverage Schrödinger’s computational expertise in target identification, lead optimization and materials property prediction. The company’s computational chemistry workflows have been used to support numerous drug candidates and novel materials initiatives, contributing to more efficient R&D pipelines and reduced experimental costs.

Headquartered in New York City, Schrödinger maintains additional offices in Europe and Asia to serve its global customer base. The company’s leadership team is led by President and Chief Executive Officer Dr. Ramy Farid, who brought extensive drug discovery experience from both industry and academia. Schrödinger’s board and scientific advisory committees include leaders from major pharmaceutical companies and academic institutions, reinforcing its commitment to advancing computational science in real-world applications.

Over its three decades of growth, Schrödinger has continuously expanded its platform capabilities, integrating machine learning techniques with physics-based methods to enhance predictive accuracy. This evolving technology stack supports a broad range of therapeutic areas—from oncology and central nervous system disorders to infectious diseases—while also enabling the design of high-performance materials for electronics, energy storage and beyond. As computational methods play an increasingly central role in research and development, Schrödinger remains at the forefront of the convergence between advanced modeling tools and life sciences innovation.

Key Stats

• Today's Range: $13.12 to $13.65
• 50-Day Range: $11.07 to $13.30
• 52-Week Range: $10.94 to $27.63
• Volume: 1.32 million shs
• Average Volume: 1.41 million shs
• Market Capitalization: $981.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.25
• Consensus Rating: Hold

Schrodinger Stock Analysis - MarketRank™

Schrodinger scored higher than 58% of companies evaluated by MarketBeat, and ranked 395th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

Schrodinger has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 4 buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

Schrodinger has a consensus price target of $20.25, representing about 52.3% upside from its current price of $13.30.

Amount of Analyst Coverage

Schrodinger has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Schrodinger are expected to grow in the coming year, from ($1.89) to ($0.94) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Schrodinger is -9.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Schrodinger is -9.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Schrodinger has a P/B Ratio of 3.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.64% of the float of Schrodinger has been sold short.

Short Interest Ratio / Days to Cover

Schrodinger has a short interest ratio ("days to cover") of 6.24.

Change versus previous month

Short interest in Schrodinger has recently decreased by 4.86%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Schrodinger does not currently pay a dividend.

Dividend Growth

Schrodinger does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: -0.03

News Sentiment

Schrodinger has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Schrodinger this week, compared to 3 articles on an average week.

Search Interest

4 people have searched for SDGR on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

8 people have added Schrodinger to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Schrodinger insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $691,160.00 in company stock.

Percentage Held by Insiders

10.10% of the stock of Schrodinger is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

79.05% of the stock of Schrodinger is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/05/2026
• Today: 5/24/2026
• AGM 2026: 6/22/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SDGR
• CIK: 1490978
• Web: www.schrodinger.com
• Phone: 212-295-5800
• Fax: N/A
• Employees: 790
• Year Founded: 1990

Price Target and Rating

• Average Price Target for Schrodinger: $20.25
• High Price Target: $25.00
• Low Price Target: $13.00
• Potential Upside/Downside: +52.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$103.26 million
• Net Margins: -40.61%
• Pretax Margin: -40.08%
• Return on Equity: -30.85%
• Return on Assets: -15.32%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.74
• Quick Ratio: 2.74

Sales & Book Value

• Annual Sales: $255.87 million
• Price / Sales: 3.84
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.25 per share
• Price / Book: 3.13

Miscellaneous

• Outstanding Shares: 73,820,000
• Free Float: 66,369,000
• Market Cap: $981.81 million
• Optionable: Optionable
• Beta: 1.57